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Abstract
To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-
exome and 850 whole-genome data from the CoMMpass Study. We identiﬁed that coding and non-coding regions
are differentially dominated by distinct single-nucleotide variant (SNV) mutational signatures, as well as ﬁve de novo
structural rearrangement signatures. Mutational signatures reﬂective of different principle mutational processes—
aging, defective DNA repair, and apolipoprotein B editing complex (APOBEC)/activation-induced deaminase activity—
characterize MM. These mutational signatures show evidence of subgroup speciﬁcity—APOBEC-attributed signatures
associated with MAF translocation t(14;16) and t(14;20) MM; potentially DNA repair deﬁciency with t(11;14) and t(4;14);
and aging with hyperdiploidy. Mutational signatures beyond that associated with APOBEC are independent of
established prognostic markers and appear to have relevance to predicting high-risk MM.
Introduction
Cancers have variable numbers of somatic mutations
that have accumulated during the life history of the
tumors as a consequence of diverse cellular processes,
including defective DNA replication or DNA repair, and
exposure to endogenous or exogenous DNA-damaging
agents1,2. Each of these processes results in mutational
signatures, which serve as proxy for the cellular processes
that have gone amiss. Mathematical deconvolution3 of
these mutational signatures in large pan-cancer series has
revealed multiple distinct signatures1, several of which are
associated with known etiologies, but many remain
unexplained1,4,5. Hence, studying the mutational sig-
natures of cancers provides a mechanism for gaining
insight into the etiological basis of tumor development.
Multiple myeloma (MM) is an incurable malignancy of
plasma cells whose pathogenesis is only partially under-
stood6. Approximately 40% of MM tumors harbor chro-
mosome translocations leading to over-expression of
oncogenes (including CCND1, CCND3, MAF, MAFB,
WHSC1/MMSET, and FGFR3) through juxtaposition to
the immunoglobulin heavy-chain locus6. Other tumors
exhibit hyperdiploidy (HD), which is also considered to be
an important initiating event6. Whole-exome sequencing
(WES) and whole-genome sequencing (WGS) studies
have so far identiﬁed over 40 driver genes that are
recurrently altered in MM6–10. However, the molecular
mechanisms giving rise to these mutations are yet to be
fully elucidated.
Here we report a comprehensive analysis of the muta-
tion signatures of over 800 MM genomes. We identify
major mutational signatures in MM reﬂective of three
known principle mutational processes: aging1,11,12, DNA
repair deﬁciency1,12–17, and activation-induced deaminase
(AID)/apolipoprotein B editing complex (APOBEC)
activity (signature 2, 9, and 13)1,13,18,19. These mutational
signatures show subgroup speciﬁcity and are reﬂective of
the molecular mechanisms involved in tumorigenesis.
Additionally, we show that information on mutational
signatures beyond that associated with APOBEC has
relevance to predicting patient prognosis and deﬁning
high-risk MM.
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Results
Genome sequencing of multiple myeloma
To examine the diversity of mutational signatures, we
analyzed overlapping WGS and WES data on 850 and 874
MM tumor-normal pairs, respectively, generated by the
Relating Clinical Outcomes in Multiple Myeloma to
Personal Assessment of Genetic Proﬁle Study (CoMM-
pass, IA10 release). The frequency of the MM major
subgroups—HD, t(11;14), t(4;14), t(14;16), t(14;20), and t
(8;14) MYC translocation—is similar to other unselected
series of patients who have been reported6 (Supplemen-
tary Table 1). We used the high-coverage WES data
(120–150×, 136,074 single-nucleotide variants [SNVs]) to
analyze coding regions and the low-coverage WGS data
(6–12×, 1,348,881 SNVs and 44,155 structural variants
[SVs]) to provide genome-wide insights into clonal
mutations associated with early processes underlying
tumorigenesis7,20.
Mutational signatures in multiple myeloma
Application of non-negative matrix factorization
(NMF)11 (Supplementary Fig. 1) to extract de novo SNV
mutational signatures did not identify any novel muta-
tional signatures (Supplementary Figs. 2 and 3), consistent
with a recent analysis on CoMMpass exome dataset21.
Overall, a total 9 of the 30 mutational signatures refer-
enced by COSMIC (Catalog of Somatic Mutations in
Cancer) were seen at >1% mutational contribution in the
WGS data (Supplementary Table 2); signature 1 related to
aging1; 2 and 13 to activity of the APOBEC family of
cytidine deaminases; 9 to polymerase η implicated with
the activity of AID during somatic hypermutation1,18,19;
signature 30 reﬂective of mismatch repair deﬁciency17;
and signature 16 which has as yet an unknown etiology.
We also extracted ﬂat signatures 3, 5, and 8 in tumors -
indicative of DNA repair deﬁciency (homolgous recom-
bination deﬁciency and nucleotide repair deﬁciency)1,12–
16. In view of the potential ambiguous assignment of these
three signatures22,23, we considered them collectively
thereafter. We did however identify ﬁve novel de novo
structural rearrangement signatures (RSs) (Fig. 1): RS1
(19% of SVs across samples)—characterized by non-
clustered deletions, large-scale tandem duplications and
inversions; RS2 (17%)—characterized by clustered trans-
locations; RS3 (13%)—characterized by inversions; RS4
(21%)—characterized by non-clustered small-scale dele-
tions and tandem duplications; RS5 (30%)—characterized
by non-clustered translocations. We therefore focused on
the nine major SNV and ﬁve de novo SV mutational
signatures for subsequent analyses.
Following on from this, we examined the contributions of
the nine major COSMIC SNV mutational signatures in both
WES and WGS datasets. The signature proﬁles recovered
from the analysis of clonal WES and exome-restricted WGS
data were highly correlated (r= 1.00, Spearman’s correlation,
Supplementary Fig. 4, Supplementary Table 3). Hence, while
Fig. 1 De novo structural rearrangements signatures. a Five de novo structural rearrangement signatures (RSs) extracted in multiple myeloma. b
Cumulative mutational contribution of the structural rearrangements across 850 whole-genome sequencing (WGS) samples. Del: deletions; tds:
tandem duplications; inv: inversions; trans: translocations
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the average sensitivity to detect clonal SNVs from the WGS
data is 20–35%7, these ﬁndings indicate that the mutational
signatures identiﬁed by WGS are valid and representative of
early mutational processes in MM. We also observed a high
concordance of mutational signature in WES data from
CoMMpass and that reported by Walker et al.8 (r= 0.86,
Spearman’s correlation, Supplementary Fig. 5, Supplemen-
tary Table 4), reﬂecting the generalizability of our observa-
tions. No signiﬁcant association between the major COSMIC
SNV signatures and those associated with rearrangements
was seen (Supplementary Table 5).
Inﬂuence of DNA replication and transcription on
mutational signatures
The impact of DNA replication and transcription on
mutational signatures was broadly consistent with
observations previously made in the analyses of other
cancers11,12,24. Speciﬁcally, an overall increased mutation
rate in late-replicating regions was shown (P < 1.0 × 10−4)
(Fig. 2a, Supplementary Table 6), with the exception of
signature 13 having higher mutation rate in early-
replicating regions (P < 1.0 × 10−4, Supplementary Fig. 6,
Supplementary Table 7), consistent with generalized
replication time-dependent DNA damage mechanisms
that operate in other cancers such as those of the breast12
and liver11. The difference in how replication timing
inﬂuences mutation rates in signatures 2 and 13, which
are both associated with APOBEC activity, suggests an
intrinsically different mutational processes linked to DNA
replication consistent with the model previously
described12.
Similarly, as previously documented, strong replicative
strand asymmetry (>30% imbalances)12 was shown with
respect to signatures 2 (Q= 4.0 × 10−16) and 13 (Q=
Fig. 2 Relationship between replication and transcription in mutational processes. a Mutation rates across different DNA replication timing
bins for single-nucleotide variants (SNVs). Whole-genome sequencing (WGS) mutation rate (blue) was estimated from low-coverage WGS data
(6–12×). Whole-exome sequencing (WES) mutation rate (orange) was estimated from high-coverage WES data (120–150×) with variants called by at
least two variant callers. b Proportion of mutations on leading and lagging strands per signature based on WGS data. Asterisks indicate signiﬁcant
asymmetry (Q < 0.05 and strand imbalances >30%). c Relationship between transcriptional level and mutation rate. The range of number of genes
across all samples included in each FPKM category (from low to high gene expression) are category 1: 4062–6800 (median 4209); category 2:
1323–4062 (median 3914); category 3: 4060–4062 (median 4061); category 4: 4060–4061 (median 4061); category 5: 4062. Error bars represent the
95% conﬁdence intervals. d Proportion of mutations on transcribed and non-transcribed strands across major signatures based on WES data. WGS:
whole-genome sequencing; WES: whole-exome sequencing; SNVs: single-nucleotide variants; FPKM: fragments per kilobase of exons per million
reads. Flat signatures include COSMIC signatures 3, 5, and 8
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4.0 × 10−16) with higher mutation in the lagging strand
(Fig. 2b, Supplementary Table 8). These ﬁndings are
consistent with APOBEC activity primarily affecting lag-
ging strands.
Overall, increased mutation rate was associated with
increased transcription, suggesting the mutagenic role
of the transcriptional process in MM (Fig. 2c). This
contrasts markedly to hepatocellular carcinoma11, sug-
gesting that transcription-associated mutagenesis may
overwhelm transcription-coupled repair in MM25.
Moreover, strikingly elevated mutation rates of both
SNVs and indels were shown for highly expressed genes
(Fig. 2c). A number of these highly expressed genes (i.e.,
FPKM (fragments per kilobase of exons per million
reads) >100), which are also frequently mutated,
including EGR126, XBP127, BTG228, DDX529, and
NFKBIA9 (Supplementary Table 9), have well-
established roles in plasma cell differentiation and
MM. The strong replicative, but weak transcriptional
mutational asymmetry (Fig. 2d, Supplementary Table
10) seen in MM is consistent with the mutual exclusivity
trend of replicative and transcriptional asymmetries
shown in many cancers24.
Mutational signatures in coding and non-coding regions
A signiﬁcant difference in all mutational signatures
within coding and non-coding regions was shown (Fig. 3,
Supplementary Table 11), implying different genomic
regions are subject to speciﬁc mutational processes,
consistent with earlier observations30. AID-attributed
signature 9 predominates in non-coding regions,
whereas exonic mutations are dominated by signatures 1,
2, and 13, implicating aging and APOBEC signatures as
important.
Relationship between mutational signatures and kataegis
Local hypermutated regions of tumor genomes, or
kataegis, have been observed in MM9,31 and other B cell
malignancies1. We examined COSMIC mutational sig-
natures contributing to kataegis (deﬁned on the basis of
average inter-mutation distance ≤1 kb;3,32 Supplementary
Table 12a), which were detected in 9% of samples (71/
874). We did not observe signiﬁcant and consistent
enrichment of COSMIC signatures at kataegis foci com-
pared to other mutations in tumors with and without
kataegis detected (Supplementary Table 12b). We iden-
tiﬁed 70 genes disrupted by kataegis (Supplementary
Table 13), including CCND1, CCND3, MAF, and FZD2,
which are often affected by chromosomal rearrange-
ments6,33. Globally, 62% of kataegis foci co-localize with
5% of somatic structural arrangement sites (Supplemen-
tary Fig. 7), consistent with previous ﬁnding that most
genomic rearrangements do not feature kataegis in nearby
regions1.
Mutational signatures and myeloma subgroups
We observed signiﬁcant association between speciﬁc
mutational signatures and MM subgroups (Table 1).
Signature 1 was enriched in HD MM (Q= 3.2 × 10−4)
consistent with the correlation between age and frequency
of HD34 (Supplementary Table 14). APOBEC-attributed
signatures 2 and 13 were enriched in MAF-translocation
subgroups—t(14;16) (Q= 1.7 × 10−15 and Q= 3.5 ×
10−19, respectively), t(14;20) (Q= 1.4 × 10−3 and Q=
6.4 × 10−6, respectively)—and to a lesser extent in t(4;14)
(only signature 2, Q= 9.3 × 10−6) consistent with previous
reports7,35. Flat COSMIC signatures, attributable to DNA
repair deﬁciency, were enriched in t(11;14) MM (Q=
3.3 × 10−4) and t(4;14) MM (Q = 0.033). We observed an
enrichment of non-clustered deletions, large-scale tan-
dem duplications, and inversions RS1 (Q= 3.8 × 10−6);
and clustered translocation RS2 (Q= 0.010) signatures in
t(4;14) MM (Supplementary Table 15). Although spec-
ulative it is possible that the t(4;14) translocation, which
leads to up-regulation of histone methyltransferase
(MMSET), may affect genomic instability through some
as yet undisclosed epigenetic mechanism.
We further explored the links between established
prognostic mutational events (1p deletion, 1q gain, 17p
deletion, and TP53 mutations) with mutational signatures
(Supplementary Table 16). Associations between
chromosome-arm events at 1p and 1q with COSMIC
signatures 2, 13, and RS1 (Q < 0.05) and between TP53
mutations tumors with RS1 (Q= 0.033) and RS2 (Q=
7.4 × 10−3) raise the possibility of causal relationships.
Mutational signatures and driver genes
To identify etiological mutational processes underlying
driver mutations in MM, we compared mutational con-
tribution in driver genes to other exonic mutations.
Overall, the same diversity of processes in driver muta-
tions was seen as in other coding mutations, but with
differences: lower contribution of signatures 2 and 13; and
higher contribution of signatures 1, 9, 16, 30, and the ﬂat
signatures in coding regions of driver genes, compared to
other exonic mutations (Fig. 4, Supplementary Table 17).
Notably, we observed an over-representation of signatures
reﬂective of aging with CCND1 and DNAH5 mutations,
and AID with EGR1 mutations (Fig. 4, Supplementary
Table 18). In contrast, a relative under-representation of
signatures 2 and 13 suggests that APOBEC mutations are
ubiquitous mutational processes and they do not speciﬁ-
cally affect driver genes. Driver genes were replicated
earlier than other coding genes (P < 2.2 × 10−16, Wilcox-
on’s rank-sum test) and we therefore assessed whether
this difference could explain enrichment of the signatures.
APOBEC signature 2 is enriched in late-replicating
regions (Supplementary Fig. 6, Supplementary Table 7);
hence, the tendency of driver genes to be replicated early
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may explain the lower frequency of signature 2 mutations
associated with driver genes. Signatures 1, 9, 16, 30, and
the ﬂat signatures were also associated with late-
replicating regions (Supplementary Fig. 6, Supplemen-
tary Table 7), but conversely were more frequently asso-
ciated with driver gene mutations. To test if the
enrichment of mutational processes in driver genes were
due to positive selection of certain mutations, we exclu-
ded all mutations that occurred at the exact same position
in multiple tumors (46% of mutations) and repeated the
analysis. Exclusion of recurrent mutations did not change
the overall results, inferring that positive selection of
speciﬁc mutations did not bias the analysis. We did not
observe any signiﬁcant transcriptional strand bias across
mutational signatures (Fig. 2d), suggesting that the
differences in mutational contribution between driver
genes and other exonic mutations are unlikely to be
inﬂuenced by transcription.
Prognostic impact of mutational signatures
We next investigated the prognostic impact of muta-
tional signatures using the prospective data from
CoMMpass. The APOBEC signature has previously been
reported to be associated with a worse patient out-
come21,35. In this study after adjusting for age, sex,
translocation status, chromosome-arm events, and TP53
status, no statistically signiﬁcant association was shown,
suggesting that APOBEC status does not represent an
independent biomarker of patient outcome: progression-
free survival (PFS: hazard ratio [HR]= 2.45, 95% con-
ﬁdence interval [CI]= 0.94–6.37, P= 0.066) and overall
survival (OS: HR= 2.81, 95% CI= 0.96–10.10, P= 0.10)
(Supplementary Table 19). We next explored whether
incorporating information on major SNVs and SV
mutational signatures could further enhance the predic-
tion of patient outcome after taking into account of
established prognostic factors. Unsupervised hierarchical
clustering provided evidence for seven distinct groups
(A–G) associated with both PFS (log-rank P= 3.4 × 10−4)
and OS (log-rank P= 0.011) (Fig. 4, Table 2, Supple-
mentary Fig. 8), with group C being enriched for HD MM,
group G is featuring tumors with 1p deletion, while group
D being characterized by APOBEC mutation, enrichment
for MAF-translocation subgroups, 1p deletion, and 1q
gain (Supplementary Table 20). Post hoc delineation
allowed us to stratify patients in seven groups into low-
(A, B, C, and E) and high-risk groups (D, G, and F)
(Supplementary Table 21). Classiﬁcation of MM based on
mutational signatures captured by these seven groups is
independent prognosis factors (Supplementary Table 22).
Notably, group F was independently associated with
adverse prognosis (PFS: HR= 1.95, 95% CI= 1.35–2.81,
P= 3.3 × 10−4 ; OS: HR = 1.47, 95% CI = 1.02–2.13, P =
0.039) (Supplementary Table 22), despite not being
associated with the high-risk features of APOBEC, t
(14;16)/t(14;20), 1p/1q/17p chromosome-arm events or
TP53 mutation status, but was typiﬁed by non-clustered
structural rearrangements (Fig. 5a, Table 2, Supplemen-
tary Fig. 8).
Discussion
Our analysis of over 800 myeloma genomes has afforded
a global overview of the mutational processes in MM
tumorigenesis. A major ﬁnding of this study is that a
combination of signatures linked to aging, APOBEC/AID,
and indicative DNA repair deﬁciency—account for
around 80% of mutations in MM. Despite the difﬁculty of
assigning ﬂat signatures (3, 5, and 8)22,23, their detection
of such proﬁles in large patient series supports the role of
Fig. 3 Contribution of each single-nucleotide variant mutational
signature in coding (blue) and non-coding (orange) regions. Flat
signatures include COSMIC signatures 3, 5, and 8
Table 1 Association of major myeloma subgroups and
mutational signature (Q < 0.05)
Subgroup Signature enrichment Suggested etiologies
Hyperdiploidy Signature 1 Aging
t(11;14) Flat signatures Potentially DNA repair
deﬁciency
t(4;14) Signatures 2, 30, and ﬂat
signatures
APOBEC and potentially DNA
repair deﬁciency
t(14;16) Signatures 2 and 13 APOBEC
t(14;20) Signatures 2 and 13 APOBEC
MYC NA NA
MYC t(8;14) MYC-translocation subgroup, APOBEC apolipoprotein B editing
complex, NA not available
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defective DNA repair in MM. By utilizing both WES and
WGS data, we were able to extract ﬁve novel structural
RSs and identify differential prevalent mutational pro-
cesses in coding (aging and APOBEC) and non-coding
regions (AID), consistent with a previous report30. Our
work supports previous ﬁndings30 in implying an early
role for AID in shaping the MM mutational landscape.
We also identiﬁed new and validated previously reported
subgroup associations with mutational signatures, allow-
ing further categorization of MM beyond simple trans-
location status and providing additional insight in the
etiological processes implicated in tumorigenesis (Fig. 6).
Mutations do not occur uniformly over the genome and
local mutation rates are modulated by replication, tran-
scription, and chromatin organization12. We observed an
enrichment of somatic mutations in late-replicating
regions, as seen across several cancers36, and highly
expressed regions. Previous analyses, which have sought
to establish the mutational proﬁle of myeloma genomes,
have been based on data solely from exome sequencing
projects. Here we have sought to provide a more com-
prehensive analysis; however, we acknowledge that the
low coverage of CoMMpass WGS raises the possibility
that we may have underestimated the global mutation
Fig. 4 Mutational signatures associated with driver genes. a Cumulative mutational contribution of mutational signatures across 50 multiple
myeloma (MM) driver genes7–10 (blue, 1679 mutations in total) and other exonic mutations (orange). b Normalized cumulative mutational
contribution of signatures with top ten contribution for most frequently mutated MM driver genes (+) vs. other mutations (−) in tumors with the
corresponding driver gene being mutated: KRAS (n= 247), NRAS (n= 204), DIS3 (n= 104), TRAF3 (n= 83), CCND1 (n= 78), BRAF (n= 70), FAM46C (n
= 70), EGR1 (n= 65), TP53 (n= 52), SP140 (n= 30), PRDM1 (n= 26), and ATM (n= 19); n: number of mutations. Flat signatures include COSMIC
signatures 3, 5, and 8
Table 2 Summary of characteristics of the seven cluster subgroups
Cluster n SV features SNV features Subgroup association Known prognostic events
A 155 Clustered translocations Enriched for t(11;14) and t
(4;14)
TP53 mutations
B 172 Non-clustered small-scaled deletions and tandem
duplications
C 138 Mixture of non-clustered SVs Enriched for hyperdiploidy
D 35 Mixture of non-clustered SVs APOBEC
mutations
Enriched for t(14;16) and t
(14;20)
1p deletion and 1q gain
E 99 Non-clustered translocations
F 97 Mixture of non-clustered SVs
G 154 Large-scaled non-clustered deletions, tandem
duplications, and inversions
Enriched for t(4;14) 1p deletion
SV structural variant, SNV single-nucleotide variant, APOBEC apolipoprotein B editing complex
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rate. The strong replicative asymmetry observed is con-
sistent with mutations in MM being predominantly
associated with APOBEC family of mutations24. In addi-
tion, we identiﬁed that coding drivers are likely to be
originated from a number of mutational processes,
including aging and DNA repair deﬁciency. In contrast,
while APOBEC enzymes appear to act more ubiquitously
within coding regions, they do not speciﬁcally affect
coding drivers.
The different MM translocation subgroups showed
striking differences in their mutational signatures, reﬂec-
tive of the cellular processes driving respective clonal
expansions (Fig. 6). As previously reported, t(14;16) and t
(14;20) MM were enriched with APOBEC signatures 2
and 137,35. This is a consequence of the over-expression of
APOBEC genes, speciﬁcally APOBEC3A and APOBEC3B,
mediated through the over-expression of MAF tran-
scription factors35. The t(4;14) subgroup was also enri-
ched with APOBEC mutational patterns, although only
for signature 2 and, to a lesser extent, as compared to
MAF-translocation subgroups. Since signatures 2 and 13
are reﬂective of different mutational processes12, we
speculate that the mutational processes associated with t
(4;14) are likely to be different from those with MAF-
translocation subgroups. In contrast, signatures indicative
of DNA repair deﬁciency were associated with t(11;14)
and t(4;14) and aging with HD. DNA breaks unsuccess-
fully repaired due to defective DNA repair may facilitate
the generation of chromosomal translocations37. Because
of the ﬂat structure of signatures 3, 5, and 8 robust insight
into etiological contribution of DNA repair deﬁciency to
MM tumorigenesis requires assiduous signature ﬁtting
and adjustment for confounding covariates23. The mole-
cular mechanisms responsible for initiating HD in MM
are unknown. However, by inference from childhood
acute lymphoblastic leukemia38, it is likely it is a con-
sequence of the simultaneous gain of chromosomes in a
single abnormal cell division. Cells failing to execute
programmed cell death in response to mitotic failure are
likely to divide asymmetrically, resulting in the generation
of aneuploidy cells39. The association between aging with
increased cell division errors40 and decreased apoptosis41
further supports a relationship between HD MM and
aging. Signatures deﬁned by large-scale structural aber-
rations were associated to varying degrees with MM
subgroups, but clustered translocations and non-clustered
deletions, large-scale tandem duplications, and inversions
showed a signiﬁcant association in t(4;14) MM.
Fig. 5 Integrative clusters based on mutational signatures and patient prognosis. a Heatmap showing proportions of rearrangement
signatures and major COSMIC (Catalog of Somatic Mutations in Cancer) signatures in unsupervised hierarchical clusters. Flat signatures include
COSMIC signatures 3, 5, and 8. The lower panel shows distribution of translocations, prognostic chromosome-arm events, and TP53 non-synonymous
mutations across all samples. b Progression-free survival and c overall survival across different cluster groups. The global P values across all cluster
groups were calculated to assess whether there is survival difference between groups
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The APOBEC mutational signatures are inextricably
linked to a high mutation load7,35 and the adverse t(14;16)
and t(14;20)MAF-translocation subgroups. We show that
molecular classiﬁcation based solely on APOBEC sig-
natures do not fully differentiate the underlying genomic
complexity in MM relevant to predicting patient out-
come. Hence, while APOBEC activity is an adverse
prognostic factor in MM21,35, using it as a sole classiﬁer
does not fully capture high-risk MM, which with geneti-
cally unstable genome is typiﬁed by complex structural
variants. Our ﬁndings support the need for considering
other mutational signatures to reﬁne prediction of patient
prognosis.
Our study does, however, suggest that analysis of
APOBEC activity together with other molecular features
at diagnosis should allow for the identiﬁcation of high-risk
MM patients that may beneﬁt from more intensive
treatment. Collectively, these data shed new light on the
diversity of cellular processes generating somatic muta-
tions in MM. Moreover, they provide a strong rationale
for integration of mutational signatures data in conven-
tional molecular proﬁling of patient tumors to tailor
therapy.
Materials and methods
Samples and datasets
All data analyzed were generated as part of the Multiple
Myeloma Research Foundation (MMRF) CoMMpass
Study (release IA10). WGS data on 850 matched tumor-
normal baseline newly diagnosed bone marrow samples
were downloaded from the database of Genotype and
Phenotype (dbGaP). Matched tumor RNAseq processed
by HTseq were used for gene expression analysis. WES
variants (detected by at least two out of three variant
callers—MuTect, Seurat, and Strelka) from 874 samples,
RNAseq, copy number variation (CNV), clinical data, and
sequencing-based ﬂuorescent in situ hybridization (Seq-
FISH) data (MMRF IA10 dataset) were downloaded from
MMRF web portal (https://research.themmrf.org/). WES
and WGS data were available for 824 samples.
Somatic mutation calling
Calling of somatic mutations was performed as descri-
bed previously7. Brieﬂy, raw WGS sequencing data were
quality checked using FastQC (v.0.11.4) and aligned using
the Burrows-Wheeler Alignment tool42 (BWA v0.7.12) to
the human genome hg19/GRCh37 assembly. SNV
Fig. 6 Contribution of major mutational processes operative in multiple myeloma. This model represents differential contribution of various
identiﬁed mutational processes in myeloma. For early mutational processes, activation-induced deaminase (AID) has the overall largest contribution
to mutational processes across all subgroups represented by a larger oval. For late mutational processes, major mutational processes with known
etiologies associated with aging, apolipoprotein B editing complex (APOBEC), DNA repair deﬁciency (DRD), and AID are depicted. Larger oval sizes
indicate larger relative contribution of the mutational process
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mutations were called using MuTect43 (v1.1.7) according
to best practices, utilizing data from dbSNP v147 and
COSMIC non-coding variants v7744. Mutations were then
ﬁltered for oxidation artifacts45 and by quality score as
described previously7. Mutations mapping to immune
hypermutated regions (429 immunoglobulin and the
major histocompatibility complex loci, each region
extended by 50 kb, as deﬁned in Ensembl v73)46 were
excluded to avoid bias from mutation as a consequence of
normal B cell development.
Determination of myeloma karyotype
Translocation status of MM tumors was based on Seq-
FISH47. HD was deﬁned as ampliﬁcation of 90% of the
chromosome in at least two autosomes7. Prognostic
chromosome-arm events (>1Mb) were deﬁned as deleted
or ampliﬁed with abs(log2 ratio) ≥0.1613 occurring at
1p12, 1p32.3, 1q21.1, 1q23.3, and 17p136.
Mutational signatures
Characterization of the 30 COSMIC mutational sig-
natures (http://cancer.sanger.ac.uk/cosmic/signatures)
and de novo extraction of signatures was performed using
Palimpsest11,48 with default parameters. We compared de
novo mutational signatures with 30 pre-deﬁned COSMIC
signatures by computing their cosine similarities1. A de
novo mutational signature was assigned to a COSMIC
signature if the cosine similarity was >0.75 as previously
advocated11. If multiple COSMIC signatures passed this
threshold, then the most similar COSMIC signature was
assigned to the de novo signature. We compared pro-
portion COSMIC mutational signatures between high-
coverage WES clonal mutations (alternate allele ratio
>0.9) and low-coverage WGS mutations restricted to
exome regions, as well as between CoMMpass exome and
Walker et al.8 exome mutations. Correlations were tested
using Spearman’s correlation. For those signatures with
an apparent ﬂat proﬁle we considered these in concert, by
combining the respective contributions of signatures 3,
5, and 8.
We used MANTA to identify somatic SVs from the
WGS data adopting default settings49. We applied the
same statistical framework used for signature analysis of
SVs implemented in Palimpsest48 to extract de novo RSs
as previously described11. Correlations between SV sig-
natures and major COSMIC pre-deﬁned SNV signatures
(>1% mutational contribution in WGS) were tested using
Spearman’s correlation. No signiﬁcant correlation was
seen after adjusting for multiple testing (i.e., Q > 0.05).
We examined the relationship between mutational sig-
natures and clinico-pathological parameters conﬁning our
analysis to the major MM subgroups—HD, t(4;14), t(11;14),
t(14;16), t(14;20), and t(8;14) MYC. Test of association
between each signature and subgroups was based on a two-
tailed Fisher’s exact test using Benjamini–Hochberg false
discovery rate procedure to address multiple testing.
We compared contribution of each mutational sig-
nature to coding and non-coding regions using WGS
data. To calculate contribution of a mutational signature
to a genomic region, we ﬁrst estimated the probability
that each mutation was due to the process underlying
each signature and calculated the cumulative probability
of all mutations in each region, as per Letouze et al.11.
After computing these probabilities, regional differences
in trinucleotide composition were accounted for when
comparing the contribution of mutational signatures
between two genomic regions (regions X and Y). Such
normalization was conducted by changing the number of
mutations from each mutational category in region X to
that expected if the trinucleotide composition of region X
was identical to the trinucleotide composition of region Y,
assuming a constant rate of mutation at positions of each
trinucleotide context. The normalized number of muta-
tions UC;Xnorm of category C in region X was calculated as:
UC;Xnorm ¼ UC;X
VC;YWX
VC;XWY
;
where UC,X is the number of mutations of category C
observed in region X, VC,X is the number of positions at
which a mutation of category C can occur in region X, and
WX is the size of region X (in base pairs). As UC;Xnorm is not
necessarily an integer, it is rounded to the closest integer
before comparisons are completed. Mutation numbers
were normalized within each tumor. Since small numbers
of mutations may impact on normalization, in each
comparison the larger region was designated as region X,
the smaller region designated as region Y.
Replication timing and replication strand bias
We used replication sequencing (Repli-seq) data gen-
erated by the ENCODE consortium for the lymphoblast
cell lines GM12878, GM06990, GM12801, GM12812, and
GM12813 to deﬁne early- and late-replicating regions, as
well as leading and lagging DNA strands using Repli-seq
signal peaks from GM12801 as previously described11,12.
Mutation rates across deciles of replication timings were
estimated globally using WGS data and for each signature,
with each mutation assigned to a single signature by
Palimpsest11,48. The replication timing slope was esti-
mated by linear regression model. To test the null
hypothesis that the slope gradients equal zero, the repli-
cation timing deciles were permuted 10,000 times.
Empirical P values were calculated as the fraction of
permutations with absolute slope values at least as great
as the absolute slope value computed using the true
replication timing deciles.
Analysis of mutational replication strand bias between
leading and lagging strands was performed across all 30
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COSMIC signatures as previously described11, using
WGS data. The Wilcoxon’s rank-sum test was used to
determine signiﬁcant difference of mutational contribu-
tion from each COSMIC signature between leading and
lagging strands. Levels of asymmetry were considered
signiﬁcant if strand imbalances were >30%12 and Q < 0.05.
Transcriptional levels and transcriptional strand bias
To correlate mutational processes with gene expression,
RNAseq data were normalized to FPKM11. For each
tumor, genes were partitioned into pentiles based on
respective FPKM. Immunoglobulin-related genes and
genes known to be highly upregulated in MM as a result
of translocations (CCND1, CCND3, FGFR3, MMSET,
MAF, MAFB, and MYC)6 were excluded to mitigate
against bias. Mutation rates of genes within each of the
ﬁve transcriptional level categories were estimated per
tumor based on WES called mutations. Average align-
ability score for highly expressed genes was based on
alignability of 75mers deﬁned by the ENCODE/CRG
GEM mappability tool50. We examined mutation rates on
transcribed and non-transcribed strands globally and for
each signature as described previously11 using Palimp-
sest11,48. Wilcoxon’s rank-sum tests, corrected for multi-
ple testing, were used to determine signiﬁcant difference
of mutational contribution from each COSMIC signature
between transcribed and non-transcribed strands. Levels
of asymmetry were again considered signiﬁcant if strand
imbalances were >30%12 and Q < 0.05.
Kataegis
We restricted our kataegis analysis to high-coverage
WES data, where we have sufﬁcient coverage to detect
local hypermutation. Kataegis foci were deﬁned as having
six or more consecutive mutations with an average
mutational distance ≤1 kb, as previously described3,32. Co-
localization of kataegis and structural rearrangements was
assessed based on the proportion of SV regions having
kataegis foci residing within 10 kb. To examine enrich-
ment of a mutational signature at kataegis regions, we
compared mutational contribution of each signature
across all mutations at kataegis foci with other mutations
in tumors with and without kataegis being detected using
Wilcoxon’s rank-sum test, corrected for multiple testing
and imposed a threshold of Q < 0.05.
Association of mutational signatures with the mutation of
driver genes
For SNV mutational signatures, Wilcoxon’s rank-sum
tests were used to compare contribution of each muta-
tional signature in coding drivers7–10 and other exonic
mutations, with normalizing for trinucleotide composi-
tion as described above. For each somatic mutation, we
estimated the probability that it was the result of each
mutational process considering the trinucleotide context
and the number of mutations attributed to each process in
the respective tumor as per Letouze et al.11. We then
compared, for each driver gene and mutational signature,
the probability distribution in mutations affecting the
driver gene as compared to all other mutations in tumors
with and without the driver gene mutated using Wilcox-
on’s rank-sum tests, imposing Benjamini–Hochberg cor-
rection for multiple testing. We evaluated all driver genes
identiﬁed in previous studies7–10 with Q < 0.05.
Association of signatures with clinical features
Multivariate Cox regression was performed to adjust for
covariates, including age at diagnosis, sex, translocation
status, and APOBEC mutational contribution (COSMIC
signatures 2 and 13). We used the ConsensusClusterPlus
R package51 to hierarchically cluster patients based on de
novo SV and major COSMIC SNV signatures (>1% con-
tribution) extracted from WGS with default settings32.
Fisher’s exact test was used to test whether clusters were
associated with MM subgroups or driver gene mutations,
imposing Benjamini–Hochberg correction for multiple
testing. The log-rank test was used to assess the differ-
ences in PFS and OS between all cluster groups. To
delineate clusters into low- and high-risk groups, pairwise
comparisons in survival distributions were performed
using the pairwise_survdiff function implemented in the
survminer R package33.
Multivariate Cox regression was performed for each
subgroup vs. other subgroups, adjusting for age at diag-
nosis, sex, translocation status, APOBEC contribution, 1p
deletion, 1q gain, 17p deletion, and TP53 non-
synonymous mutations.
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